Manufacturer of Axitinib Powder - GLP-1 Protected Amino Acid for Side Chain Modification – Gentolex
Manufacturer of Axitinib Powder - GLP-1 Protected Amino Acid for Side Chain Modification – Gentolex Detail:
Product Detail
|
NO. |
Products |
CAS No. |
Application |
Key Quality Indicator |
||||
|
Purity |
Isomer |
SI * |
Max * |
Moisture |
||||
|
1 |
Fmoc-Lys(Mtt)-OH | 167393-62-6 | Lysine side chain modification |
≥99.0% |
≤0.1% |
≤0.2% |
≤0.3% |
≤1.0% |
|
2 |
Fmoc-Lys(Alloc)-OH | 146982-27-6 | Lysine side chain modification |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤1.0% |
|
3 |
Fmoc-Lys(ivDde)-OH | 150629-67-7 | Lysine side chain modification |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
4 |
Fmoc-Lys(Mmt)-OH | 159857-60-0 | Lysine side chain modification |
≥98.0% |
≤0.2% |
≤0.3% |
≤0.5% |
≤1.0% |
|
5 |
Fmoc-Glu-OtBu | 84793-07-7 | LiraglutideSemaglutide |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤1.0% |
|
6 |
Glu-OtBu | 45120-30-7 | LiraglutideSemaglutide |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤1.0% |
|
7 |
Octadecanedioic acid | 871-70-5 | Semaglutide |
≥99.0% |
/ |
≤0.2% |
≤0.3% |
≤1.0% |
|
8 |
Octadecanedioic acid mono-tert-butyl ester | 843666-40-0 | Semaglutide |
≥99.0% |
/ |
≤0.2% |
≤0.3% |
≤1.0% |
|
9 |
tBu-OOC-C16-CO-Glu-OtBu | 1188328-39-3 | SemaglutideFragment A |
≥98.0% |
≤0.2% |
≤0.5% |
≤0.5% |
≤1.0% |
|
10 |
AEEA | 134978-97-5 | SemaglutideAlbuvirtide |
≥99.0% |
/ |
≤0.2% |
≤0.3% |
≤1.0% |
|
11 |
AEEA-OH.HCl | 134979-01-4 | SemaglutideAlbuvirtide |
≥99.0% |
/ |
≤0.2% |
≤0.3% |
≤1.0% |
|
12 |
Fmoc-AEEA-OH | 166108-71-0 | SemaglutideAlbuvirtide |
≥99.0% |
/ |
≤0.2% |
≤0.3% |
≤1.0% |
|
13 |
Boc-AEEA-OH | 108466-89-3 | Semaglutide |
≥99.0% |
/ |
≤0.2% |
≤0.3% |
≤1.0% |
|
14 |
AEEA-AEEA | 1143516-05-5 | Semaglutide |
≥98.0% |
≤0.2% |
≤0.5% |
≤0.5% |
≤1.0% |
|
15 |
Fmoc-AEEA-AEEA-OH | 560088-89-3 | SemaglutideFragment B |
≥98.0% |
≤0.2% |
≤0.5% |
≤0.5% |
≤1.0% |
|
16 |
Octa(OtBu)-Glu(ɑ-OtBu)-AEEA-AEEA-OH | 1118767-16-0 | SemaglutideFragment C |
≥98.0% |
≤0.2% |
≤0.5% |
≤0.5% |
≤1.0% |
|
17 |
tBu-OOC-C16-CO-Glu(AEEA-AEEA-NHS)-OtBu | 1118767-15-9 | SemaglutideFragment D |
≥96.0% |
≤0.5% |
≤1.0% |
≤1.0% |
≤1.0% |
|
18 |
Fmoc-Lys(tBu-OOC-C16-CO-Glu(AEEA-AEEA)-OtBu)-OH | 1662688-20-1 | Semaglutide Fragment E |
≥96.0% |
≤0.5% |
≤1.0% |
≤1.0% |
≤1.0% |
|
19 |
Boc-His(Trt)-OH | 32926-43-5 | The end is histidine |
≥99.5% |
≤0.1% |
≤0.1% |
≤0.2% |
≤4.0% |
|
20 |
Fmoc-Aib-OH | 94744-50-0 | Semaglutide |
≥99.5% |
/ |
≤0.1% |
≤0.2% |
≤1.0% |
|
21 |
Boc-His(Trt)-Aib-OH | 2061897-68-3 | Semaglutide |
≥99.0% |
≤0.1% |
≤0.2% |
≤0.3% |
≤2.0% |
|
22 |
Fmoc-Glu(OtBu)-Gly-OH | 866044-63-5 | GLP-1 analogue |
≥99.5% |
≤0.1% |
≤0.2% |
≤0.2% |
≤1.0% |
|
23 |
Boc-His(Trt)-Aib-Glu(OtBu)-Gly-OH | 1169630-31-2？ | Semaglutide Fragment F |
≥98.0% |
≤0.2% |
≤0.5% |
≤0.5% |
≤1.0% |
|
24 |
Boc-His(Trt)-Aib-Glu(OtBu)-Gly-NHS | 1169630-40-3 | Semaglutide Fragment G |
≥96.0% |
≤0.5% |
≤1.0% |
≤1.0% |
≤1.0% |
|
25 |
Fmoc-Arg(pbf)-Gly-OH | 660846-80-0 | GLP-1 analogue |
≥99.5% |
≤0.1% |
≤0.2% |
≤0.2% |
≤1.0% |
|
26 |
Fmoc-Ala-Ala-OH | 87512-31-0 | GLP-1 analogue |
≥99.5% |
≤0.1% |
≤0.2% |
≤0.2% |
≤1.0% |
|
27 |
Fmoc-Thr(tBu)-Phe-OH | 1260609-75-3 ? | GLP-1 analogue |
≥99.5% |
≤0.1% |
≤0.2% |
≤0.2% |
≤1.0% |
|
28 |
Palmitic acid | 1957/10/3 | Liraglutide Fragment 1 |
≥99.0% |
/ |
≤0.2% |
≤0.3% |
≤1.0% |
|
29 |
Palm-Glu-OtBu | NA | Liraglutide Fragment 2 |
≥98.0% |
≤0.2% |
≤0.5% |
≤0.5% |
≤1.0% |
|
30 |
Palm-Glu(NES)-OtBu | NA | Liraglutide Fragment 3 |
≥96.0% |
≤0.5% |
≤1.0% |
≤1.0% |
≤1.0% |
|
31 |
Fmoc-Lys(Palm-Glu-OtBu)-OH | 1491158-62-3 | Liraglutide |
≥98.0% |
≤0.2% |
≤0.5% |
≤0.5% |
≤1.0% |
|
32 |
Hexadecanedioic acid | 505-54-4 | Insulin degludec |
≥99.0% |
/ |
≤0.2% |
≤0.3% |
≤1.0% |
|
33 |
Hexadecanedioic acid mono-tert-butyl ester | 843666-27-3 | Insulin degludec |
≥99.0% |
/ |
≤0.2% |
≤0.3% |
≤1.0% |
|
34 |
tBu-OOC-C14-CO-Glu-OtBu | NA | Insulin degludec Fragment I |
≥98.0% |
≤0.2% |
≤0.5% |
≤0.5% |
≤1.0% |
|
35 |
tBu-OOC-C14-CO-Glu(NES)-OtBu | NA | Insulin degludec Fragment II |
≥96.0% |
≤0.5% |
≤1.0% |
≤1.0% |
≤1.0% |
SI *= Specific Impurity
Max*= Max Unknown Impurity
Other Indicator:
- Acetic Acid: ≤0.02% (All Products)
- Ethyl Acetate: ≤0.5% (All Products)
- Alcohol: ≤0.5% (All Products)
Sanitization
Sanitization of distribution system, including loop and storage tank is performed by Pasteurization. When Pasteurization sanitization is performed, the purified water in tank is heated up to 80°C and start to circulate by distribution system. The sanitization lasts 1 hour after reaching 80°C. Sanitization is performed every quarter. The purified water system sanitization logbook was checked with no excursion highlighted.
Product detail pictures:
Related Product Guide:
Our business has been focusing on brand strategy. Customers' pleasure is our best advertising. We also offer OEM company for Manufacturer of Axitinib Powder - GLP-1 Protected Amino Acid for Side Chain Modification – Gentolex , The product will supply to all over the world, such as: Haiti, Holland, Atlanta, Qualified R&D engineer will be there for your consultation service and we will try our best to meet your requirements. So please feel free to contact us for inquiries. You'll be able to send us emails or call us for small business. Also you are able to come to our business by yourself to get further knowing of us. And we will surely give you the best quotation and after-sale service. We're ready to build stable and friendly relations with our merchants. To achieve mutual success, we will make our best efforts to build a solid co-operation and transparent communication work with our companions. Above all, we are here to welcome your inquiries for any of our goods and service.
By Molly from Bahrain - 2018.12.11 11:26
The company keeps to the operation concept "scientific management, high quality and efficiency primacy, customer supreme", we have always maintained business cooperation. Work with you,we feel easy!
By Erin from Peru - 2017.08.18 11:04
